Evidence map›Paper›PMID 33289280›Full record

Trial reportThe oncologist2021

High-Flow Nasal Cannula Therapy for Exertional Dyspnea in Patients with Cancer: A Pilot Randomized Clinical Trial.

David Hui, Donald A Mahler, Liliana Larsson, Jimin Wu, Saji Thomas, Carol A Harrison, Kenneth Hess, Juan Lopez-Mattei, Kara Thompson, Daniel Gomez and 4 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02357134 (High-Flow Oxygen for Exertional Dyspnea in Cancer Patients), which is not on this map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02357134 phase2unknown statusnot on this map

High-Flow Oxygen for Exertional Dyspnea in Cancer Patients

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2015 to 2023Enrolled74ConditionsDyspnea, Malignant NeoplasmArmsOxygen Therapy, Quality-of-Life Assessment, Questionnaire Administration, Respiratory Therapy
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. High flow nasal therapy in the management of hypoxemic dyspnea at the end of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  18. High flow nasal therapy in the management of hypoxemic dyspnea at the end of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

David HuiDepartment of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-2733-6607
Donald A MahlerDepartment of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Liliana LarssonDepartment of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
Jimin WuDepartment of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.
Saji ThomasDepartment of Respiratory Care, MD Anderson Cancer Center, Houston, Texas, USA.
Carol A HarrisonDepartment of Behavioral Science, MD Anderson Cancer Center, Houston, Texas, USA.
Kenneth HessDepartment of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.
Juan Lopez-MatteiDepartment of Cardiology, MD Anderson Cancer Center, Houston, Texas, USA.
Kara ThompsonDepartment of Cardiology, MD Anderson Cancer Center, Houston, Texas, USA.
Daniel GomezDepartment of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Melenda JeterDepartment of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Steven LinDepartment of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Karen Basen-EngquistDepartment of Behavioral Science, MD Anderson Cancer Center, Houston, Texas, USA.
Eduardo BrueraDepartment of Palliative Care, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USDartmouth College · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Strategies for Persistent Agitated Delirium in Palliative CareR01CA225701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUI, DAVID · 2019 to 2022
$1.9M
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer PatientsR01CA214960 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUI, DAVID · 2017 to 2020
$1.6M
Palliative Therapies for Refractory Delirium in Advanced CancerR21NR016736 · NINR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUI, DAVID · 2017 to 2018
$455k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA214960NCI NIH HHS R01 CA225701NINR NIH HHS R21 NR016736
6 · The paper itself

Abstract

backgroundExertional dyspnea is common in patients with cancer and limits their function. The impact of high-flow nasal cannula on exertional dyspnea in nonhypoxemic patients is unclear. In this double-blind, parallel-group, randomized trial, we assessed the effect of flow rate (high vs. low) and gas (oxygen vs. air) on exertional dyspnea in nonhypoxemic patients with cancer. PATIENTS AND

methodsPatients with cancer with oxygen saturation >90% at rest and exertion completed incremental and constant work (80% maximal) cycle ergometry while breathing low-flow air at 2 L/minute. They were then randomized to receive high-flow oxygen, high-flow air, low-flow oxygen, or low-flow air while performing symptom-limited endurance cycle ergometry at 80% maximal. The primary outcome was modified 0-10 Borg dyspnea intensity scale at isotime. Secondary outcomes included dyspnea unpleasantness, exercise time, and adverse events.

resultsSeventy-four patients were enrolled, and 44 completed the study (mean age 63; 41% female). Compared with low-flow air at baseline, dyspnea intensity was significantly lower at isotime with high-flow oxygen (mean change, -1.1; 95% confidence interval [CI], -2.1, -0.12) and low-flow oxygen (-1.83; 95% CI, -2.7, -0.9), but not high-flow air (-0.2; 95% CI, -0.97, 0.6) or low-flow air (-0.5; 95% CI, -1.3, 0.4). Compared with low-flow air, high-flow oxygen also resulted in significantly longer exercise time (difference + 2.5 minutes, p = .009), but not low-flow oxygen (+0.39 minutes, p = .65) or high-flow air (+0.63 minutes, p = .48). The interventions were well tolerated without significant adverse effects.

conclusionOur preliminary findings support that high-flow oxygen improved both exertional dyspnea and exercise duration in nonhypoxemic patients with cancer. (ClinicalTrials.gov ID: NCT02357134). IMPLICATIONS FOR PRACTICE: In this four-arm, double-blind, randomized clinical trial examining the role of high-flow nasal cannula on exertional dyspnea in patients with cancer without hypoxemia, high-flow oxygen, but not high-flow air, resulted in significantly lower dyspnea scores and longer exercise time. High-flow oxygen delivered by high-flow nasal cannula devices may improve clinically relevant outcomes even in patients without hypoxemia.

Indexed as

CannulaNeoplasmsCross-Over StudiesDyspneaFemaleHumansMaleMiddle AgedPilot ProjectsClinical trialDyspneaExercise toleranceNeoplasmsOxygen

Identifiers

PMID33289280
PMCPMC8342581
OpenAlexW3108332518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.